See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eid
Social Media
Natural Disasters
Artificial Intelligence
Donald Trump
Baseball
Tariffs
Stock Markets
Soccer
European Union
Real Estate
Education
Published • loading... • Updated

Virion Therapeutics Reports Positive Clinical Data with VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure, at APASL 2025 Global Liver Meeting

  • Virion Therapeutics presented positive clinical data for VRON-0200, showing safety and tolerability in chronically HBV-infected patients at APASL 2025.
  • Thirty percent of patients exhibited significant CD8+ T cell responses after VRON-0200, indicating immunogenicity.
  • Patients experienced significant HBV surface antigen declines ranging from-0.4 to-2.3 log10 IU/mL by Day 154.
  • Experts highlight VRON-0200 as a promising candidate to achieve a functional cure for chronic HBV infection.
Insights by Ground AI
Does this summary seem wrong?

26 Articles

All
Left
1
Center
10
Right
1
The Berkshire EagleThe Berkshire Eagle
+24 Reposted by 24 other sources
Center

Virion Therapeutics Reports Positive Clinical Data with VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure, at APASL 2025 Global Liver Meeting

Highlights from the Data Presentation

Read Full Article
pressreach.compressreach.com

Virion Therapeutics Reports Positive Clinical Data with VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure, at APASL 2025 Global Liver Meeting - PressReach

Highlights from the Data Presentation Safety, immunogenicity, and anti-HBV activity, presented in chronically HBV-infected patients following a single, prime-only, or a prime and boost, intramuscular injection of VRON-0200 Over 7,680 patient safety days (N=27), VRON-0200 was well tolerated, with no serious adverse events (SAEs), study patient discontinuations, or clinical laboratory abnormalities observed VRON-0200 induced CD8+ T cell responses…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 83% of the sources are Center
83% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

TBNweekly broke the news in on Friday, March 28, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal